- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00003731
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES: I. Assess the therapeutic activity of temozolomide as first line chemotherapy in patients with recurrent oligodendroglial tumors after radiation therapy. II. Assess the objective response and duration of response of these patients given this treatment. III. Characterize the acute side effects of temozolomide in this patient population.
OUTLINE: This is an open label, multicenter study. Patients receive oral temozolomide on days 1-5. Courses are repeated every 28 days. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 15-33 patients will be accrued for this study.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Bamberg, Allemagne, D-96049
- Nervenklinik Bamberg
-
Berlin, Allemagne, D-12200
- Universitaetsklinikum Benjamin Franklin
-
Regensburg, Allemagne, DOH-9-3053
- Klinikum der Universität Regensburg
-
-
-
-
-
Brussels, Belgique, 1070
- Hopital Universitaire Erasme
-
Brussels, Belgique, 1090
- Academisch Ziekenhuis der Vrije Universiteit Brussel
-
Leuven, Belgique, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Lille, France, 59037
- Centre Hospitalier Regional de Lille
-
Marseille, France, 13385
- CHU de la Timone
-
Nancy, France, 54035
- CHU de Nancy - Hopital Neurologique
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Nice, France, 06002
- Hôpital Pasteur
-
Villejuif, France, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Padova (Padua), Italie, 35128
- Azienda Ospedaliera di Padova
-
Rome, Italie, 00161
- Istituti Fisioterapici Ospitalieri - Roma
-
-
-
-
-
Lisbon, Le Portugal, 1093
- Instituto Portugues de Oncologia de Francisco Gentil
-
-
-
-
-
Nijmegen, Pays-Bas, NL-6252 HB
- University Medical Center Nijmegen
-
Rotterdam, Pays-Bas, 3075 EA
- Rotterdam Cancer Institute
-
Utrecht, Pays-Bas, 3508 GA
- Academisch Ziekenhuis Utrecht
-
-
-
-
Scotland
-
Edinburgh, Scotland, Royaume-Uni, EH4 9NQ
- Western General Hospital
-
-
-
-
-
Bratislava, Slovaquie, 833 03
- Postgraduate Medical Institute
-
-
-
-
-
Aarau, Suisse, 5001
- Kantonspital Aarau
-
Basel, Suisse, CH-4031
- University Hospital
-
Bern, Suisse, CH-3010
- Inselspital, Bern
-
Lausanne, Suisse, CH-1011
- Centre Hospitalier Universitaire Vaudois
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with at least 25% oligodendroglial elements Recurrent or progressive disease following radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits from the present recurrence No new neurological deficits interfering with daily activities No tumor causing midline shift or brain stem compression due to which a rapid deterioration is to be expected in case of no response No signs of increased intracranial pressure No extracranial disease
PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignant or nonmalignant diseases interfering with follow-up No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified Other: No other concurrent investigational drugs No other concurrent antitumor agents
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006 Oct;42(15):2499-503. doi: 10.1016/j.ejca.2006.05.021. Epub 2006 Aug 17.
- van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003 Jul 1;21(13):2525-8. doi: 10.1200/JCO.2003.12.015.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EORTC-26971
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .